Novel therapeutic strategies for cdk4/6 inhibitors in metastatic castrate-resistant prostate cancer

Research output: Contribution to journalArticlepeer-review

Abstract

The majority of patients with castrate-resistant prostate cancer will have meta-static disease at the time of diagnosis. Investigative efforts on new therapeutics for this patient population have improved with the development of androgen signaling inhibitors, such as abiraterone and enzalutamide, and PARP inhibitors, such as rucaparib and olaparib, to accompany the previously FDA-approved docetaxel, cabazitaxel, sipuleucel-T, and Radium 223. However, new therapeutic strategies are necessary to prolong survival as progression after these agents is inevitable. CDK4/6 inhibitors have advanced the field of estrogen receptor positive breast cancer treatment and are being investigated in prostate cancer given the role of androgen receptor signaling effects on the cell cycle. Response to CDK4/6 inhibitors may be predicted by the tumors’ genomic profile and may provide insight into combinatory therapy with CDK4/6 inhibitors in order to delay resistance or provide synergistic effects. Here, we review the use of CDK4/6 inhibitors in prostate cancer and potential combinations based on known resistance mechanisms to CDK4/6 inhibitors, prostate cancer regulatory pathways, and prostate-cancer-specific genomic alterations.

Original languageEnglish (US)
Pages (from-to)10499-10513
Number of pages15
JournalOncoTargets and Therapy
Volume13
DOIs
StatePublished - 2020

Keywords

  • CDK4/6 inhibitors
  • Combination therapy
  • Genomics
  • Metastatic castrate-resistant prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Novel therapeutic strategies for cdk4/6 inhibitors in metastatic castrate-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this